Thermo Fisher Scientific Inc. (NYSE:TMO) Position Boosted by IHT Wealth Management LLC

IHT Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 37.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,375 shares of the medical research company’s stock after purchasing an additional 917 shares during the period. IHT Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $1,712,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in TMO. Grayhawk Investment Strategies Inc. acquired a new position in shares of Thermo Fisher Scientific in the second quarter worth about $26,000. Lowe Wealth Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 160.0% in the third quarter. Lowe Wealth Advisors LLC now owns 52 shares of the medical research company’s stock worth $26,000 after buying an additional 32 shares during the period. New Millennium Group LLC acquired a new position in shares of Thermo Fisher Scientific in the second quarter worth about $29,000. Toth Financial Advisory Corp boosted its holdings in shares of Thermo Fisher Scientific by 7,300.0% in the third quarter. Toth Financial Advisory Corp now owns 74 shares of the medical research company’s stock worth $38,000 after buying an additional 73 shares during the period. Finally, Coston McIsaac & Partners acquired a new position in shares of Thermo Fisher Scientific in the second quarter worth about $44,000. Institutional investors own 85.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. SVB Leerink raised their target price on shares of Thermo Fisher Scientific from $620.00 to $630.00 and gave the stock an “outperform” rating in a report on Thursday, February 2nd. StockNews.com cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Friday, March 10th. Deutsche Bank Aktiengesellschaft started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, December 13th. They set a “buy” rating and a $620.00 price target for the company. Barclays raised their price target on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock an “overweight” rating in a report on Thursday, February 2nd. Finally, Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $613.00 to $670.00 and gave the stock an “overweight” rating in a report on Thursday, February 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $647.00.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $557.09 on Friday. The firm has a market cap of $214.72 billion, a PE ratio of 31.60, a PEG ratio of 1.83 and a beta of 0.79. The firm’s 50 day moving average price is $565.67 and its 200 day moving average price is $545.12. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.15 and a current ratio of 1.48. Thermo Fisher Scientific Inc. has a twelve month low of $475.77 and a twelve month high of $618.35.

Thermo Fisher Scientific (NYSE:TMO – Get Rating) last issued its quarterly earnings data on Wednesday, February 1st. The medical research company reported $5.40 earnings per share for the quarter, beating the consensus estimate of $5.19 by $0.21. Thermo Fisher Scientific had a net margin of 15.47% and a return on equity of 21.42%. The firm had revenue of $11.45 billion for the quarter, compared to analyst estimates of $10.41 billion. During the same quarter last year, the firm earned $6.54 earnings per share. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.72 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 14th. Stockholders of record on Wednesday, March 15th will be given a $0.35 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.30. The ex-dividend date of this dividend is Tuesday, March 14th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.81%.

Insider Activity

In other news, CEO Marc N. Casper sold 7,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 13th. The shares were sold at an average price of $544.49, for a total value of $4,083,675.00. Following the transaction, the chief executive officer now owns 66,655 shares of the company’s stock, valued at $36,292,980.95. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Marc N. Casper sold 1,600 shares of the firm’s stock in a transaction on Tuesday, February 14th. The shares were sold at an average price of $571.96, for a total value of $915,136.00. Following the sale, the chief executive officer now owns 128,705 shares in the company, valued at $73,614,111.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 7,500 shares of the firm’s stock in a transaction on Monday, March 13th. The stock was sold at an average price of $544.49, for a total transaction of $4,083,675.00. Following the completion of the sale, the chief executive officer now owns 66,655 shares in the company, valued at approximately $36,292,980.95. The disclosure for this sale can be found here. Insiders have sold a total of 30,100 shares of company stock valued at $16,966,971 over the last 90 days. 0.43% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.